Radiation therapy used most often for prostate cancer regardless of decision-making factors
the ONA take:
The most common treatment for prostate cancer is radiation therapy, regardless of cancer stage, prostate-specific antigen (PSA) level, and prognosis and risk rating.
In an analysis of Surveillance, Epidemiology and End Results (SEER)-Medicare linked data for 37,621 men with a prostate cancer diagnosis from 2004 to 2007, the researchers found radiation therapy was the most common treatment, followed by radical prostatectomy and other treatments including watchful waiting or active surveillance (WW-AS).
Radiation treatment was the most common regardless of stage, PSA level, and prognosis and tumor rating; however, PSA level influenced the choice of radical prostatectomy.
Clinical stage, as well as prognosis and tumor rating, influenced patients to choose WW-AS, but cancer stage, PSA level, and prognosis and risk rating prompted a decision to undergo androgen-deprivation therapy (ADT).
The authors reported that increased use of treatments in men with prostate cancer and underuse of active surveillance in men with low-risk disease remain.
Their study concludes that further research into what drives treatment choices among both patients and their physicians are needed.
Most common treatment for prostate cancer is radiation therapy, regardless of cancer stage.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|